The patent has also been granted in New Zealand, South Africa and India and is pending in other countries.
The novel compounds covered by Via’s latest patent exhibit phoshodiesterase (PDE) inhibition, principally PDE4 inhibition, and may be active in certain PDE subtypes. Via will evaluate these compounds in its preclinical research program, and will work with its collaborators to test their utility in the treatment of cardiovascular inflammation and other inflammatory conditions.
“Given the potential for PDE4 inhibition as a means of treating other diseases mediated by inflammation, we believe it is important for us to initiate a broad development program from the outset” stated Lawrence Cohen, Via’s CEO and president.